drugset / Trial / NCT05345938

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

NCT05345938

Phase 1/2 Terminated 1 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, single-arm, phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of mitoxantrone hydrochloride liposome injection in subjects with acute myeloid leukemia (AML).

Timeline

Start
2022-06-14
Primary completion
2022-11-19
Completion
2022-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 30 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 36 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 40 mg/m2 Intravenous